PT  - JOURNAL ARTICLE
AU  - Wahby, Sakar
AU  - Fashoyin-Aje, Lola
AU  - Osgood, Christy L.
AU  - Cheng, Joyce
AU  - Fiero, Mallorie H.
AU  - Zhang, Lijun
AU  - Tang, Shenghui
AU  - Hamed, Salaheldin S
AU  - Song, Pengfei
AU  - Charlab, Rosane
AU  - Dorff, Sarah E.
AU  - Ricks, Tiffany K.
AU  - Barnett-Ringgold, Kimberly
AU  - Dinin, Jeannette
AU  - Goldberg, Kirsten B.
AU  - Theoret, Marc R.
AU  - Pazdur, Richard
AU  - Amiri-Kordestani, Laleh
AU  - Beaver, Julia A
TI  - FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC)
AID  - 10.1158/1078-0432.CCR-20-3119
DP  - 2020 Jan 01
TA  - Clinical Cancer Research
PG  - clincanres.3119.2020
4099  - http://clincancerres.aacrjournals.org/content/early/2020/11/07/1078-0432.CCR-20-3119.short
4100  - http://clincancerres.aacrjournals.org/content/early/2020/11/07/1078-0432.CCR-20-3119.full
AB  - On April 22, 2020, the FDA granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY; Immunomedics, Inc.) for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Approval was based on data from the IMMU-132-01 trial, a single-arm, multicohort, multicenter, Phase 1/2 trial of sacituzumab govitecan. The assessment of efficacy was based on 108 patients with mTNBC who had previously received at least two prior lines of therapy in the metastatic setting and who received sacituzumab govitecan 10 mg/kg intravenously (IV). The assessment of safety was based on 408 patients with advanced solid tumors who had received sacituzumab govitecan at doses up to 10 mg/kg IV. The primary efficacy endpoint was investigator-assessed objective response rate (ORR) and duration of response (DoR) was a key secondary endpoint. The ORR was 33.3% [36/108, 95% CI: 24.6, 43.1], and median DoR among responders was 7.7 months (95% CI: 4.9, 10.8). The most common adverse reactions occurring in ≥25% of patients were nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia, constipation, rash, decreased appetite, and abdominal pain. This article summarizes the FDA review process and data supporting the approval of sacituzumab govitecan.